Pharmacogenetics (DPYD / UGT1A1 only)
DPYD and/or UGT1A1 pharmacogenetic testing for drug response and efficacy (Germline DNA).
Pharmacogenetics (panel testing)
Pharmacogenetic panel testing of markers for drug response and efficacy (Germline DNA).
CYP2C19 POCT
Point-of-care molecular testing (POCT) of CYP2C19 for optimisation of antiplatelet therapy (Artificial Buccal swabs)
MT-RNR1 POCT
Point-of-care molecular testing (POCT) of MT-RNR1 for avoidance of aminoglyocside induced hearling loss in neonates (Artificial Buccal swabs)
Microsatellite Instability testing (MSI) [Tissue]
Microsatellite Instability testing testing (FFPE).
Oncogene panel testing [Tissue]
This EQA scheme is offered to help laboratories using high through put technologies (e.g., NGS, MassArray etc.) to accurately validate assay sensitivity and specificity. For specific tumour types, please register for the relevant scheme (e.g., Lung, Melanoma, Colorectal, Ovarian, Breast, Prostate, Pancreas). High quality reference materials are provided covering a range of genes with variants with ddPCR quantified allelic frequencies.